Evaluation of the Oral Antimitotic Agent (ABT-751) in Dogs with Lymphoma

Silver, Mitchell; Rusk, A.W.; Phillips, Brenda; Beck, Eduardo; Jankowski, Marcin; Philibert, J.; Hahn, Klaus-Jürgen; P. Hershey, E.; McKeegan, Evelyn; Bauch, Joy; Krivoshik, Andrew; Khanna, C.

doi:10.1111/j.1939-1676.2012.00892.x

Public

Evaluation of the Oral Antimitotic Agent (ABT-751) in Dogs with Lymphoma

Published in Journal of Veterinary Internal Medicine • Feb 28, 2012

Authors:

Mitchell Silver

A.W. Rusk

Brenda Phillips

Abstract

BACKGROUND: ABT-751 is a novel orally available antimitotic agent that targets microtubule polymerization. This mechanism may suggest potential activity in canine lymphoma. OBJECTIVE: Determine a maximum tolerated dose for ABT-751, and assess long-term tolerability and activity in canine lymphoma. A...

Subject

Medicine

Tolerability

Canine Lymphoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!